Last reviewed · How we verify
Intramuscular Olanzapine Depot
Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.
Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia maintenance treatment, Bipolar I disorder maintenance treatment.
At a glance
| Generic name | Intramuscular Olanzapine Depot |
|---|---|
| Also known as | LY170053, Zyprexa Adhera |
| Sponsor | Eli Lilly and Company |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Olanzapine antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to mood stabilization and reduction of negative symptoms. The depot formulation provides sustained drug release over weeks to months, improving medication adherence in chronic psychiatric conditions.
Approved indications
- Schizophrenia maintenance treatment
- Bipolar I disorder maintenance treatment
Common side effects
- Weight gain
- Sedation
- Hyperglycemia
- Hyperlipidemia
- Injection site reactions
- Akathisia
- Extrapyramidal symptoms
Key clinical trials
- Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia (PHASE3)
- Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder (PHASE3)
- A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder (NA)
- A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder (PHASE3)
- Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia (PHASE3)
- Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia (PHASE3)
- Pharmacokinetic Characterization of Intramuscular Olanzapine Depot (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intramuscular Olanzapine Depot CI brief — competitive landscape report
- Intramuscular Olanzapine Depot updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI